Nanotherapeutic that can cross blood-brain barrier reported in journal
The University of Delaware’s Emily Day is a part of a team of researchers that has developed a nanotherapeutic capable of penetrating the blood-brain barrier.
Previously believed impossible, the groundbreaking development could have implications in the treatment of Glioblastoma multiforme (GBM), a lethal form of malignant brain tumors that is considered one of the deadliest human cancers. It may also benefit research for neurodegenerative diseases such as Parkinson’s disease, traumatic brain injury and multiple forms of cancer.
Led by researchers at Northwestern University, where Day conducted post-doctoral research, the team discovered that spherical nucleic acids (SNAs), tiny spherical gold nanoparticles densely coated with nucleic acids, have unique properties that allow them to pass through the blood-brain barrier and attack brain cancer.
The technology works by targeting Bcl2L12, a gene important in tumor progression.
“We believe that the SNA particles pass through by binding to scavenger receptors present in the cells lining the blood-brain barrier,” Day explained. “Once past the barrier, the SNA particles travel through the brain tissue and infiltrate tumor cells, where they interfere with the tumor cell’s genetic machinery to prevent the Bcl2L12 gene from being expressed.”
When administered systemically in cell and rodent models, the SNAs delivered nucleic acids to tumors without help from cationic carriers or other chemical modifications, lowered the expression of Bcl2L12 and effectively reduced tumor burden.
“Generally speaking we saw about a 20 percent increase in animal survival rates with this treatment, and a five-fold reduction in tumor growth without adverse side effects,” said Day, assistant professor of biomedical engineering at UD.
This discovery establishes SNAs as a promising new class of therapeutic gene regulation agents capable of treating disease through systemic injection, according to the research team’s findings published as a cover article in Science Translational Medicine, a publication of the American Association for the Advancement of Science.
Co-first authors on the paper were Day, Samuel Jensen and Caroline Ko, and their interdisciplinary team included researchers from Northwestern University’s departments of chemistry, biomedical engineering, molecular biosciences, neurology, neurobiology, and the International Institute for Nanotechnology. The research was led by Chad Mirkin, professor in Northwestern University’s Department of Chemistry, and Alexander Stegh, professor, in the Department of Neurology.
Future work on the project will include studies to determine safety and efficacy issues necessary for human trials and scaling the technology for manufacturing.
The Latest Google Headlines on:
The Latest Bing News on:
- Is this New Jersey high school connected to over 120 brain tumors?on May 27, 2022 at 3:30 pm
A New Jersey school was allegedly connected to over 120 cases of brain tumors. Here’s what radioactive test results say.
- 107 cases of brain tumors led to investigation at NJ high school: Mayor announces resultson May 27, 2022 at 2:22 pm
When a former student at Colonia High School in Woodbridge, New Jersey, realized that he, his wife and his sister all had brain tumors, he wondered if something about their high school could have ...
- 'Our hearts are broken' | Georgia officer, Army veteran dies of brain cancer at 29on May 27, 2022 at 10:41 am
A southeast Georgia police officer described as a "beloved" member of the force died on Thursday after a "courageous battle" with brain cancer at the age of 29, the Chatham County Police Department ...
- He struggled to remember the right words. It was an aggressive form of brain canceron May 27, 2022 at 10:32 am
A cancerous glioblastoma caused Bruce Lowder's speech problems. He enrolled in some clinical trials to have more time with his family and to help others.
- He struggled to find his words. A ‘nasty’ brain tumor was to blameon May 27, 2022 at 9:48 am
Bruce Lowder kept forgetting words. They soon learned that an aggressive glioblastoma was the cause. He participated in clinical trials to help others.
- Student with brain cancer granted dying wish to graduate high schoolon May 27, 2022 at 9:47 am
MICHELLE: A YOUNG MAN WHO HAS BEEN BATTLING BRAIN CANCEROR F ALMOST A DECADE HAD ONE LAST WISH -- TO GRADUATE FROM BOONE HIGH SCHOOL. STEWART: THANKS TO HOSCEPI WORKERS AND SCHOOL STAFF, TODAY HIS ...
- High schooler with terminal brain cancer gets dying wish to graduateon May 27, 2022 at 6:48 am
A young Florida man who has been battling terminal brain cancer had one last wish granted Thursday. Although he is technically still a few credits shy of graduating, thanks to hospice workers and ...
- Strain for the Brain 5K run/walk; benefits brain tumor researchon May 27, 2022 at 6:31 am
Join FOX6 in supporting Strain for the Brain to benefit brain tumor research. The event takes place at the Harley-Davidson Museum on Sunday, June 5.
- Inovio Pharma Shares Rise After Brain-Cancer-Treatment Dataon May 27, 2022 at 5:27 am
By Michael Dabaie Inovio Pharmaceuticals Inc. shares were up 4.6%, to $1.83, in premarket trading Friday after the company reported survival results from ...
- Investigation by Woodbridge, N.J. finds no link between brain tumors and Colonia High Schoolon May 26, 2022 at 4:08 pm
The investigation is over, but not everyone is satisfied. On Thursday, the city of Woodbridge said it found no links. As CBS2's Kevin Rincon reported, the finding flies in the face of dozens of people ...
The Latest Google Headlines on:
The Latest Bing News on:
- Diversified Polymeric Micelles for Osteosarcoma Therapyon May 18, 2022 at 5:01 pm
The simple, structured presentation coupled with relevant information on the subject of micelle-based nanotherapeutic drug delivery make this monograph an essential handbook for pharmaceutical ...
- EV Biologics Signs MSA with LONZA Cell & Gene Therapyon May 17, 2022 at 2:03 pm
The MSA enables EV Biologics to accelerate its nanotherapeutic biomanufacturing process and producer-cell line development through Lonza’s global infrastructure and deep expertise in cell and ...
- EV Biologics Signs MSA with LONZA Cell & Gene Therapyon May 17, 2022 at 9:50 am
The MSA enables EV Biologics to accelerate its nanotherapeutic biomanufacturing process and producer-cell line development through Lonza's global infrastructure and deep expertise in cell and gene ...
- Dr. Victor Moyo, MBChB, Joins OncoPep as Chief Medical Officeron May 17, 2022 at 9:46 am
Prior to LEAF, Moyo was at Merrimack Inc where he worked on numerous biological and nanotherapeutic programs including Onivyde® which is approved for metastatic pancreatic cancer Moyo earned his ...
- EV Biologics Signs MSA with LONZA Cell & Gene Therapyon May 17, 2022 at 9:00 am
HOUSTON, TX / ACCESSWIRE / May 17, 2022 / EV Biologics Corp, OTC PINK:YECO, today announced that it has signed a Manufacturing Services Agreement (MSA) with Lonza for development of stem/progenitor ...
- NIR-II-responsive nickel-based therapeutics provide new solution for synergistic oncotherapyon May 16, 2022 at 5:00 pm
This experiment demonstrated a kind of bifunctional nanotherapeutic based on NIR-II-responsive PUNNC for synergistic tumor therapy.
- Liposomes as Drug Delivery Systems for the Treatment of TBon August 17, 2020 at 11:48 pm
 According to the mentioned disadvantages of classical chemotherapy and to the hope that has been put in a nanotherapeutic approach, this article will provide a state of art in the use of ...